The Food and Drug Administration has given record-fast approvals to Novartis ' (nyse: NVS - news - people ) Gleevec and Millennium 's (nasdaq: MLNM - news - people ) Velcade based on relatively early-stage data in these diseases.
Under pressure to reduce research costs and win fast-track approvals, drug companies do 43% of their clinical trials abroad, up from 14% ten years ago.